图像引导放疗用于妇科肿瘤再程放疗:免疫治疗前时代的肿瘤控制概率与正常组织并发症概率
该机构队列纳入2020至2023年既往接受过放疗的复发性或第二原发妇科恶性肿瘤患者70例,再程放疗采用IG-VMAT、SBRT和/或IGBT。中位随访37个月,3年野内控制率、PFS和OS分别为63.5%、62.4%和68%;再程放疗剂量≥50 Gy和無病间期≥24个月与野内控制改善独立相关,累积EQD2≥130 Gy10预测≥3级毒性。
要点
- 再程放疗剂量≥50 Gy与野内控制改善独立相关(p=0.04)。
- 無病间期≥24个月与野内控制改善独立相关(p=0.004)。
- 累积EQD2≥130 Gy10预测≥3级胃肠道/泌尿生殖毒性(p=0.008)。
核心结论
- 图像引导放疗技术用于复发性妇科肿瘤再程放疗可获得良好的局部控制且毒性可接受。
研究设计与样本
- 单机构队列研究,纳入2020至2023年既往接受过放疗的复发性或第二原发妇科恶性肿瘤患者70例。
- 再程放疗采用图像引导容积调强弧形治疗(IG-VMAT)、立体定向体部放疗(SBRT)和/或图像引导近距离放疗(IGBT)。
- 采用Kaplan-Meier法估计野内控制、无进展生存(PFS)和总生存(OS),采用单因素和多因素分析评估野内控制的预后因素,不良事件按CTCAE 5.0版报告。
主要发现
- 70例患者中宫颈癌62例(88.5%)、子宫内膜癌6例(8.5%)、外阴阴道癌2例(2.8%),鳞状细胞组织学占81.4%。
- 再程放疗中位剂量为50 Gy(IQR 42.2-64.2 Gy);34/70例(48.6%)接受全身化疗,无贝伐珠单抗或免疫治疗。
- 中位随访37个月,3年野内控制率、PFS和OS分别为63.5%、62.4%和68%。
- 再程放疗剂量≥50 Gy和無病间期≥24个月与野内控制改善独立相关(p=0.04,0.004)。
关键数值与推荐
- 再程放疗剂量≥50 Gy与野内控制改善独立相关(p=0.04)。
- 無病间期≥24个月与野内控制改善独立相关(p=0.004)。
- 累积EQD2≥130 Gy10预测≥3级胃肠道/泌尿生殖毒性(p=0.008)。
临床怎么用
- 对既往接受过盆腔放疗的复发性妇科肿瘤患者,可考虑采用IG-VMAT、SBRT和/或IGBT进行再程放疗。
- 再程放疗剂量≥50 Gy可能改善野内控制,但需关注累积EQD2≥130 Gy10时≥3级毒性风险。
- 無病间期≥24个月的患者可能从再程放疗中获得更好的野内控制。
局限性
- 单机构回顾性队列研究,样本量70例。
- 研究时期为免疫治疗前时代,队列中无患者接受贝伐珠单抗或免疫治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Management of recurrent gynaecological cancers after previous pelvic radiation is challenging. This institutional cohort describes clinical outcomes with image-guided radiotherapy techniques. MATERIALS AND METHODS: From 2020 to 2023, patients with recurrent or second primary gynaecological malignancies previously treated with radiotherapy were included. Reirradiation was delivered using image-guided volumetric arc therapy (IG-VMAT), stereotactic body radiotherapy (SBRT), and/or image-guided brachytherapy (IGBT) as clinically appropriate. Infield control, progression-free survival (PFS), and overall survival (OS) were estimated using the Kaplan-Meier method. Prognostic factors for infield control were assessed with uni- and multivariate analyses. Adverse events were reported (CTCAE version 5.0). The dose-response effect for tumour control and late effects were estimated. RESULTS: Seventy patients underwent reirradiation. Of these 62 (88.5 %), 6 (8.5 %), and 2 (2.8 %) had cervical cancer, endometrial cancer, and vulvovaginal cancer, respectively. The majority of patients had squamous cell histology (81.4 %). Fifty-nine patients (84.2 %) were treated for local and/ or nodal recurrence, and 11 patients were treated (15.8 %) for second primary cancer. The median reirradiation dose was 50 Gy (IQR 42.2-64.2 Gy). In this cohort, 34/70 (48.6 %) patients received systemic chemotherapy, and no Bevacizumab or Immunotherapy. With a median follow-up of 37 months, the 3-year infield control, PFS, and OS were 63.5 %, 62.4 %, and 68 %, respectively. Reirradiation dose ≥50 Gy and disease-free interval ≥24 months were independently associated with improved infield control (p = 0.04, 0.004). Grade ≥3 gastrointestinal/genitourinary toxicity occurred in 18.5 % patients. Cumulative EQD2 ≥130 Gy10 predicted for grade ≥3 toxicity (p = 0.008). CONCLUSIONS: Image-guided radiotherapy techniques for reirradiation achieve excellent local control with acceptable toxicity in patients with recurrent gynaecological cancers.
引用
- Chopra S, Manjunath NV, Gupta A, et al. Gynaecological reirradiation with image-guided radiotherapy: Tumour Control Probability and Normal Tissue Complication Probability in pre-immunotherapy era. Radiother Oncol. 2025. PMID: 40738345. doi:10.1016/j.radonc.2025.111064
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。